gilead sciences inc lakeside drive foster city california gilead sciences annual report f wwwgileadcom gilead sciences annual report gilead sciences biopharmaceutical company discover develop commercialize innovative therapeutic area unmet medical need company mission advance care patient suffer lifethreatening disease worldwide headquarter foster city california gilead operation north america europe asia pacific ambisome cayston complera emtriva eviplera gilead gilead science gilead logo design hepsera letairis ranexa stribild truvada viread vistide volibris register trademark gilead sciences inc relate company atripla register trademark bristolmyer squibb gilead sciences llc lexiscan register trademark astella llc tamiflu register trademark hoffmannla roche inc macugen register trademark eyetech inc prescribe information gilead product available wwwgileadcomwe inspire opportunity address unmet medical need patient lifethreatene disease world nosellot ngise welcome gilead cover katie live hiv infant grow maryland face stigma young age disease despite experience maintain positive outlook life credit supportive family friend know firsthand importance support people face health challenge katie plan devote career help need recently graduate university central florida aim pursue master degree public health dedication stribild approve hiv effectiveness safety profile convenience single tablet regimen standard care hiv single hivaids tablet regiman combine multiple drug require hiv treatment helps ensure patient medicine avoid partial dose lead resistance therapy end achieve turn significant milestone approval food drug administration fda stribild fixeddose formulation gilead medicine oncedaily pill point treatmentnave patient single tablet regimen hiv join atripla complera prescribe antiretroviral regimen united states europe stribild new tool hiv prevention july truvada product approve fda combination safe sex practice reduce risk hiv uninfected adult high risk strategy call preexposure prophylaxis prep international aids conferencethe large gathering scientist clinician public health expert advocate commit eradicate diseasea sense grow optimism prevail approval truvada prep note milestone help slow spread hiv community great risk offer new hope bring epidemic control great progress diagnosis linkage care individual hiv occur year hiv prevention remain challenge world jamie diagnose hiv order cope fear experienced time diagnosis jamie educate extensively disease work closely doctor find right treatment doctor encouragement begin antiretroviral therapy right away today interest jamie maintain passion travel outdoorsrecently visit small fishing village mexico patagonia innovation transform treatment paradigm current interferonbased regimen available treat hepatitis c remain new treatment challenge patient safety issue effect variable response rate burdensome injection gilead advance development oral hepatitis c medicine goal option improve tolerability convenience increase cure rate november report percent sustain virologic response rate svr treatmentnave chronic genotype hepatitis c patient enrol phase trial evaluate alloral combination sofosbuvir gs ledipasvir gs ribavirin base datum sofosbuvir ledipasvir hepatitis c coformulated single pill study phase trial sofosbuvir accelerate clinical development follow acquisition pharmasset january move quickly expand clinical testing hepatitis c therapy phase trial explore sofosbuvir combination agent genotype patient population ongoing new study initiate enrol participant patient provider interest able complete enrollment trial week addition evaluate multiple hepatitis c drug combination diverse genotype patient population investigate way shorten therapy year matter week edward gane md professor medicine university auckland new zealand leading expert treat chronic hepatitis c principal investigator electron study gilead investigational agent sofosbuvir dr gane excite potential alloral regimen treatment effective tolerable patient hcv rna undetectable week complete therapy excellence insight molecular biology scientific understanding biological mechanism underlie cancer rapidly increasingand understanding seek lead potential breakthrough therapy area focus gilead involve investigational new agent specifically target intracellular signal pathway responsible tumor growth improve approach involve target extracellular matrix support system help enable solid tumor growth importantly certain target agent few treatment effect conventional treatment chemotherapy chronic lymphocytic leukemia cancer image color modify improve patient outcome gilead develop new treatment option target range cancer explore utility medication combination therapy disease difficult treat work inform robust understanding biology focus interrupt key pathway involve formation replication cancerous cell tessa st rose clinical research coordinator stanford university help people blood cancer enroll research study investigational therapy drive potential help patient family critical time see role essential bridge patient oftencomplex clinical trial process tessa work closely patient answer question explain research protocol schedule study visitsall important step search find new treatment today future stockholder employee friend exceptional year gilead life lose international aids conference efficacy viread dose times sciences company achieve revenues washington dc july new optimism lower help improve tolerability billion include product sale emerge fuel improvement hiv pre therapy interim finding ongoing billion deliver medicine vention diagnosis care world phase study show tafcontaine record number people disease single tablet regimen achieve similar world importantly significant gilead remain forefront advance virologic response stribild early progress advance rd program hiv treatment development initiate phase study evaluate therapeutic area new single tablet regimen august taf single tablet regimen food drug administration fda june mark th anniversary approve stribild company single july fda approve truvada gilead found company grow tablet regimen stribild combine medi preexposure prophylaxis prepmarke rapidly biotech startup multi cation complete hiv treatment regiman time product approve national biopharmaceutical company oncedaily pill approach help allow reduce risk hiv infection highrisk employee span country patient adhere fully suppressive adult combination safe sex practice continent organization inspire course therapy easily consis key advancement fight hiv opportunity address need tently critical successful result decade work involve patient involve improve management disease commercial investigator academic medical institution patient care patient like katie cover organization introduce product imme funding agency jamie physicians like edward gane diately follow approval stribild clinical trial participant world leave right gregg h alton executive vice president corporate medical affair kevin young cbe executive vice president healthcare provider atripla complera achieve commercial operation robin l washington senior vice president chief financial officer john c martin phd chairman tessa st rise close billion product sale addition clinical intervention chief executive officer norbert w bischofberg phd executive vice president research development chief scientific prep gilead continue support educa officer katie l watson senior vice president human resources john f milligan phd president chief operating officer hivaid longterm goal ensure hiv tion outreach increase access hiv patient work prescriber test care worldwide partner scientific advancementsin drug design option choose single tablet regimen conduct hiv test formulation deliveryand public health right important progress represent important contribution advancementsin disease awareness screen development program public health help diagnose infected ing linkage carecollectively tenofovir alafenamide taf gs individual connect care stem global hivaid epidemic nucleotide reverse transcriptase inhibitor november preventive service remarkable statement year taf able exhibit great antiviral task force recommend routine hiv testing aids pandemic million adolescent adult age participant n remain hcv rna unde diabetes addition new generation late area oncology company increase access closing require private insurer cover cost tectable week complete therapy sodium current inhibitor develop advance novel therapy target patient globe summary organization strong screening svr phase trial explore sofosbuvir gs currently phase key molecular signal pathway resource obtain medi business foundation billion combination genotype patient study potential treat ischemic extracellular matrix involve growth cine need work expand treatment revenue continue liver disease population ongoing initial regulatory heart disease arrhythmias area survival certain cancer exist access possible company significant progress advance new thera filing expect half pulmonary arterial hypertension pah ing treatment option limit idelalisib pharmasset acquisition complete comprehensive patient assistance program pie solidify future growth appropriate commercial infrastructure phase research program design gs pik delta inhibitor currently january leadership position provide medicine united states assemble support potential advance understanding disease evaluate phase study indo establish drug development cost lowincome uninsured patient like thank employee launch sofosbuvir pathology define clinical profile lend nonhodgkin lymphoma chronic chronic hepatitis c virus hcv infection copay assistance coupon program commitment excellence hard work letairis include potential lymphocytic leukemia simtuzumab year advance nucleo help unable afford copayment like acknowledge invaluable liver meeting sixyear clinical trial product combination progressing phase study assess tide nsb inhibitor sofosbuvir gs associate commercial health insurance input board director data viread treatment chronic oral pah treatment frontline therapy safety efficacy treat pancreatic oncedaily fixeddose combination tablet program hepatitis b virus hbv infection present colorectal cancer myelofibrosis contain sofosbuvir nsa inhibitor thank continue support ed show sustained virological area respiratory disease cayston certain fibrotic disease recent com ledipasvir gs phase testing gilead expand access look forward year aheadand biochemical response patient inhale antibiotic approve treat cystic pletion ym biosciences acquisition goal transform paradigm hcv care medication resourcelimite part progress believe evidence viral resistance result fibrosis cf patient pseudomona selective jak inhibitor momelotinib gs develop alloral treatment regimen worldinclude develop country patient world reinforce viread position mostpre aeruginosa evaluate phase cyt add grow oncology high cure rate well tolerability hivaid epidemic affect million scribe medicine chronic hbv united studies assess efficacy treat inflammation pipeline phase study great convenience patient people december approximately state european country bacterial infection associate noncf momelotinib myelofibrosis plan currently available option million patient develop world bronchiectasis result trial second half receive gilead hiv medicine expect november datum show cardiovascular respiratory doubling number patient john c martin phd efficacy sofosbuvir ledipasvir plus riba oncologyinflammation reach chairman chief executive officer addition evaluate gs virin present liver meeting therapeutic area look way phase clinical trial compound annual conference american associa appropriately expand use available show preclinical study block respiratory tion study liver disease interim medicine advance investigational syncytial virus rsv rsv pathogen result phase study suggest therapy address unmet need infect human respiratory tract lead week course medicine patient patient cardiovascular disease ranexa forwardlooke statement infect genotype hcvthe com bronchiolitis pneumonia estimate annual report include forwardlooke statement clinical study product candidate include anticipate timing achievement certain oral late sodium current inhibitor newborn hospitalize development milestone regulatory filing launch statement prediction involve risk uncertainty actual result differ materially mon strain united states currently indicate chronic angina refer gilead annual report year end december attach report risk uncertainty affect gilead business gilead disclaim rsv year united states difficult treatresulte percent explore phase study type obligation update forwardlooke statement report financial focus area highlight hivaid product sale total revenue gilead working develop generation hiv millions millions single tablet regimen effective tolerable convenient provide certain advantage exist treatment option particularly important individual hiv diagnose bring care lifelong treatment require control virus conduct clinical trial tenofovir alafen amide taf gs taf able exhibit great antiviral efficacy viread dose time low improve tolerability hiv therapy phase study examine oncedaily single tablet regimen taf emtriva integrase inhibitor elvitegravir boost agent cobicistat compare stribild patient new hiv therapy ambisome ranexa letairis hiv medicine reduce level virus antiviral franchise blood undetectable level ultimate goal develop cure gilead scientist engage early stage research identify novel therapeutic agent help eradicate hiv infection earning share operate cash flow eu marketing approval submit million stribild elvitegravir mgcobicistat mg emtricitabine mgtenofovir disoproxil fumarate mg potential indication hivaid eu marketing approval submit cobicistat pharmacokinetic enhancer potential indication hivaid elvitegravir integrase inhibitor potential indication hivaid earning share calculation phase period present reflect twoforone stock single tablet regimen elvitegravircobicistat split effective january emtricitabinetenofovir alafenamide nongaap dilute earning share potential indication hivaid exclude impact aftertax acquisition relate expense restructure phase expense stockbase single tablet regimen darunavircobicistat compensation expense emtricitabinetenofovir alafenamide nongaap dilute earning share potential indication hivaids gaap dilute exclude aftertax acquisitionrelate expense earning share stockbase compensation n eao rn ng ina ga sp pd eil ru st d ar e expense nongaap diluted earning share exclude aftertax acquisitionrelate expense restructuring expense stockbase compensation expense roberto tascione general manager italy gilead sciences focus area focus area liver disease cardiovascular disease chronic hepatitis b c cause persistent viral cardiovascular disease diabetes represent infection frequently lead liver cirrhosis liver considerable public health burden worldwide failure cancer significant unmet medical need new therapeutic option patient living condition chronic hepatitis b treat viread ongoing clinical study show regression number clinical study ongoing explore cirrhosis year therapy approximately use ranexa currently indicate treatment percent patient baseline liver biopsy data chronic angina potentially benefit specific available patient chronic hepati population patient include study evaluate tis b lifelong antiviral therapy require ranexa patient chronic angina type continue research combination approach diabete additional clinical trial evaluate ranexa increase cure rate chronic hepatitis b patient patient unable control type diabetes include oral medicine therapeutic vaccine currently available medication patient undergo stenting procedure gilead advance broad diverse pipeline investigational treatment chronic hepatitis c working identify potential new therapy ultimate goal develop alloral regiman cardiovascular disease explore mechanism work strain virus result action underlie ranexainhibition late sodium high cure rate short treatment duration current research lead phase clinical today therapy complete phase study evaluate ranexa combination drone study sofosbuvir gs single agent admin darone paroxysmal atrial fibrillation identify istere standard care therapy positive result novel molecule gs potential trial announce late early chronic hepatitis c phase treat cardiovascular disease ischemic support initial regulatory application phase ranolazine late sodium current inhibitor heart disease arrhythmia sofosbuvir nucleotide nsb inhibitor potential indication incomplete compound additionally develop single tablet regimen sofosbuvir ledipasvir revascularization postpci advancement pulmonary arterial oncedaily fixeddose combination sofosbuvir nucleotide nsb inhibitornsa inhibitor ranolazine late sodium current inhibitor potential indication type diabetes hypertension treatment letairis ledipasvir gs phase study phase gs ns protease inhibitor phase need optimize use exist agent people live chronic hepatitis c gs nonnucleoside nsb inhibitor ranolazinedronedarone fixeddose gilead continue conduct phase gs pangenotypic nsa inhibitor combination viral disease include hiv patient study answer question optimal patient care potential indication paroxysmal atrial await liver transplantation phase fibrillation define clinical benefit letairis gs tlr agonist evaluate hepatitis c treatment diverse phase broad patient population difficulttotreat patient group chronic hepatitis b gs potential indication ischemic heart disease phase gs tlr agonist arrhythmia tenofovir alafenamide nucleotide reverse transcriptase inhibitor liver fibrosis nonalcoholic steatohepatitis primary sclerose cholangitis diana brainard md senior director clinical research liver phase rico calara phd associate director medical sciences disease gilead science simtuzumab monoclonal antibody gilead sciences phil pang md director clinical research liver disease gs janelle goin pharmd associate director medical sciences gilead sciences gilead sciences focus area focus area respiratory oncology disease inflammation gilead product category respiratory oncology inflammation new focus area disease tamiflu remains lead antiviral gilead make rapid progress identify treatment prevention seasonal influenza target investigational cancer therapy evaluate clinical study inhale antibiotic cayston indicate treat respiratory pseudomona aeruginosa people lead oncology candidate include idelalisib gs cystic fibrosis cf inherit disease affect momelotinib gscyt idelalisib lung digestive system investigate small molecule drug design inhibit pik potential cayston treat bacterial infection delta signal pathway think drive certain people noncf bronchiectasis cancer cell development compound stud ie clinical trial chronic lymphocytic leukemia simtuzumab gs monoclonal antibody indolent nonhodgkin lymphoma momelotinib investigate potential treatment idiopathic investigational jak inhibitor show promise pulmonary fibrosis lifethreatening scar treatment myelofibrosis blood disorder lung know cause gs study molecule add gilead development pipeline respiratory syncytial virus rsv infects acquisition ym biosciences human respiratory tract lead bronchiolitis pneumonia rsv common microbial simtuzumab gs monoclonal antibody cause lung airway infection infant develop target loxl enzyme think young child involve solid tumor growth study pancreatic colorectal cancer myelofibrosis addition gs syk inhibitor clinical phase phase study bcell malignancy aztreonam inhalation solution idelalisib pik delta inhibitor potential indication noncf bronchiectasis potential indication chronic lymphocytic partnership explore new therapeutic leukemia phase target oncology multiyear collaboration simtuzumab monoclonal antibody idelalisib pik delta inhibitor potential indication idiopathic pulmonary potential indication indolent nonhodgkin yale school medicine search genetic fibrosis lymphoma basis underlie molecular mechanism gs phase form cancer potential indication respiratory syncytial momelotinib jak inhibitor virus potential indication myelofibrosis simtuzumab monoclonal antibody potential indication myelofibrosis simtuzumab monoclonal antibody potential indication pancreatic cancer simtuzumab monoclonal antibody potential indication colorectal cancer gs pik delta inhibitor potential indication lymphoid malignancy phase gs syk inhibitor derek marshall research scientist biology gilead science potential indication bcell malignancy vivian barry associate scientist biology gilead science develop single agent combination idelalisib rhyannon spangler senior research associate biology anne mathew director marketing gilead sciences gilead sciences focus area market access treatment product hivaid liver disease respiratory atripla hepsera advance therapy lifethreatening disease efavirenz mgemtricitabine adefovir dipivoxil cayston require innovationnot laboratory mgtenofovir disoproxil chronic hepatitis b aztreonam inhalation solution fumarate mg medicine deliver patient glaxosmithkline inc cystic fibrosis p aeruginosa priority ensure people need therapy hivaids china japan saudi arabia bristolmyers squibb company access regardless ability pay western europe canada live world merck co inc rest world tamiflu oseltamivir phosphate ensure access develop world country viread disease medicine treat place tenofovir disoproxil fumarate influenza b complera chronic hepatitis b f hoffmannla roche ltd great burden develop world country worldwide emtricitabinerilpivirinetenofovir japan tobacco inc japan fewest resources address challenge gilead disoproxil fumarate work manufacturer regional hivaid local distributor generic licensee low price janssen rd ireland market eviplera europe cardiovascular enable generic production certain gilead medi cine hivaids chronic hepatitis b begin transfer technology stribild emtriva new hiv single tablet regimen partner emtricitabine begin process produce generic version hivaid patient low middleincome country japan tobacco inc japan letairis ambisome coordinate support educational activity medi ambrisentan amphotericin b liposome cal clinical worker ensure proper use pulmonary arterial hypertension injection medicine group severe fungal infection access highlight stribild glaxosmithkline inc astellas pharma inc canada mark year fiveyear expand half million hiv patient low elvitegravir mgcobicistat mg market volibris outside dainippon sumitomo pharma co ltd partnership world health organization middleincome country receive gilead emtricitabine mgtenofovir japan disoproxil fumarate mg therapiesrepresenting approximately onethird control visceral leishmaniasis vl seconddeadli people treat hiv country hivaid lexiscan parasitic disease malaria gilead provide japan tobacco inc japan regadenoson injection ambisome treat patient vl indian manufacturer south african coronary vasodilation macugen manufacturer license produce pegaptanib sodium injection astellas pharma inc canada ensure access united states generic version hiv chronic hepatitis b rapidscan europe select ther neovascular wet agerelate macular recognize financial difficulty americans medicine develop country truvada market degeneration face today economy gilead establish half people united states take emtricitabinetenofovir eyetech inc gilead hiv medicine receive federal disoproxil fumarate pfizer inc outside comprehensive package patient assis state program substantially discount hivaids tance solution include provide medicine price japan tobacco inc japan eligible patient charge offer copay ranexa ranolazine coupon program patient private insurance regardless income long history chronic angina vistide viread menarini group europe cidofovir injection work state aids drug assistance program tenofovir disoproxil fumarate cmv retinitis patient aid adap increase access hiv treatment voluntary hivaid price freeze additional discount adap japan tobacco inc japan hiv medicines run image show represent actual size corporate gilead sciences inc lakeside drive information foster city california gilead sciences annual report f wwwgileadcom board director senior leadership team robert schooley md transfer agent registrar john c martin phd john c martin phd professor medicine head communication concern stock chairman chief executive officer chairman chief executive officer division infectious disease transfer requirement lose certificate gilead science vice chair department medicine change address john f milligan phd university california san diego direct transfer agent james denny president chief operating officer lead independent director eric j topol md computershare gilead sciences board director norbert w bischofberg phd director scripps translational washington boulevard executive vice president science institute jersey city nj john f cogan phd research development chief academic officer scripps health usa senior fellow hoover institution chief scientific officer professor genomics stanford university scripps research institute wwwcomputersharecom gregg h alton etienne f davignon executive vice president bernard wagner md equal opportunity employer minister state corporate medical affair emeritus research professor gilead sciences proud equal chairman genfina pathology new york university opportunity employer extend kevin young cbe medical center employment man woman carla hill executive vice president culturally diverse background chair chief executive officer commercial operation corporate secretary environment respect individual hill company international gregg h alton difference recognize employee consultant robin l washington executive vice president corporate integral member company senior vice president medical affair workforce reflect value kevin e lofton chief financial officer celebrate individual president chief executive officer independent register public grow team catholic health initiative katie l watson accountant senior vice president ernst young llp john w madigan human resource palo alto california retired chairman chief executive officer scientific advisory board corporate headquarters tribune company joel r huff phd chairperson gilead sciences inc retire vice president lakeside drive gordon e moore phd medicinal chemistry foster city usa retired chairman merck research laboratory chief executive officer wwwgileadcom intel corporation paul berg phd cahill professor stockholder inquiry nicholas g moore biochemistry emeritus inquiry stockholders retire global chairman stanford university school medicine potential investor company pricewaterhousecooper welcome receive francis v chisari md prompt response direct richard j whitley md professor virology immunology request information distinguish professor scripps research institute loeb scholar chair pediatric investor relation professor pediatric microbiology peter b dervan phd gilead sciences inc medicine neurosurgery bren professor chemistry lakeside drive university alabama birmingham california institute technology foster city usa gayle edlund wilson paul e klotman md chair ralph parsons president chief executive officer information gilead foundation john e clara b whitmore available wwwgileadcom professor baylor college medicine woldolsen stock list retire president human health john w mellors md gilead common stock trade intercontinental division professor medicine nasdaq global select stock market merck co inc chief division infectious disease symbol gild university pittsburgh school director emeritus gilead sciences medicine annual meeting board director annual meeting stockholder george p shultz phd eugene r schiff md hold wednesday distinguish fellow leonard miller professor medicine westin san francisco hoover institution director schiff liver institute airport hotel stanford university director center liver disease university miami school medicine gilead sciences annual report gilead sciences biopharmaceutical company discover develop commercialize innovative therapeutic area unmet medical need company mission advance care patient suffer lifethreatening disease worldwide headquarter foster city california gilead operation north america europe asia pacific ambisome cayston complera emtriva eviplera gilead gilead science gilead logo design hepsera letairis ranexa stribild truvada viread vistide volibris register trademark gilead sciences inc relate company atripla register trademark bristolmyer squibb gilead sciences llc lexiscan register trademark astella llc tamiflu register trademark hoffmannla roche inc macugen register trademark eyetech inc prescribe information gilead product available wwwgileadcom gilead sciences inc lakeside drive foster city california gilead sciences annual report f wwwgileadcom gilead sciences annual report gilead sciences biopharmaceutical company discover develop commercialize innovative therapeutic area unmet medical need company mission advance care patient suffer lifethreatening disease worldwide headquarter foster city california gilead operation north america europe asia pacific ambisome cayston complera emtriva eviplera gilead gilead science gilead logo design hepsera letairis ranexa stribild truvada viread vistide volibris register trademark gilead sciences inc relate company atripla register trademark bristolmyer squibb gilead sciences llc lexiscan register trademark astella llc tamiflu register trademark hoffmannla roche inc macugen register trademark eyetech inc prescribe information gilead product available wwwgileadcom